Submission of Monitoring Agency Report for the half year ended and year ended on 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aptus Pharma's SME IPO raised ₹13.02 crore in September 2025. CARE Ratings, acting as the Monitoring Agency, has confirmed NIL deviation in the utilization of IPO proceeds for the half year ended March 31, 2026. All ₹13.02 crore has been fully deployed across four categories: ₹1.63 crore for capital expenditure (office premises, furniture, industrial racks), ₹8.00 crore for working capital (vendor payments), ₹1.91 crore for general corporate purposes, and ₹1.48 crore for offer expenses. No material deviations or delays were observed, and the company completed all objects as per the offer document by March 2026. Notably, the stock price has surged to ₹360 as of April 24, 2026, compared to the IPO issue price of ₹70 per share.
Positive for shareholders: IPO proceeds have been fully and properly utilized with no deviations, indicating the company is executing its stated plans as promised during the IPO. The substantial appreciation in share price reflects market confidence.